KLRS today
$1.57-$0.09 (-5.42%)close Nov 13, 2026Trend
DailyUptrend (starting)
4 hourStrong Bearish
1 hourStrong Bearish
15 minStrong Bearish
5 minStrong Bearish
Daily trend turns down below $1.78
Key levels
Resistance$2.16
Resistance$1.92
Latest news & SEC filings
AnalystCitizens keeps Market Outperform on Kalaris Therapeutics, cuts target to $20
EarningsKalaris Therapeutics posts smaller quarterly loss than expected
EarningsKalaris Therapeutics Posts Q3 2026 Results, Gives Business Update
All KLRS news →About Kalaris Therapeutics
Kalaris Therapeutics is a biopharmaceutical company in the clinical phase of development, working on therapies for common retinal conditions with few treatment options. Its main candidate, TH103, is an anti-VEGF protein given by eye injection, intended to stay in the eye longer than existing drugs, for patients with neovascular age-related macular degeneration and other retinal diseases driven by VEGF. The company runs human studies of this candidate and is based in the United States.
Based on the company's 10-K filed Mar 17, 2026.
Nasdaq · Healthcare
Kalaris Therapeutics, Inc. (KLRS)
What Is the Price Target for KLRS?
SEPT Low Target
$14.00
SEPT Mid Target
$14.00
SEPT High Target
$17.00
Analyst Consensus
$14.00
Is KLRS a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for KLRS.
Start Free Trial →Is KLRS Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$12.07
7
Moat Score
NONE
4/9
Piotroski Score
-1.5
Altman Z-Score
What Is Smart Money Doing with KLRS?
Insider Signal
NEUTRAL
2 buys / 1 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
MEDIUM
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| AKKARAJU SRINIVAS | director 10% owner | Buy | 244,300 | $1.2M | May 20, 2026 |
| AKKARAJU SRINIVAS | director 10% owner | Sale | 66,906 | - | May 20, 2026 |
| AKKARAJU SRINIVAS | director 10% owner | Buy | 14,937 | - | May 20, 2026 |
| AKKARAJU SRINIVAS | director 10% owner | Buy | 4,471 | - | May 20, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →KLRS Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
94.49%
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
Dark Pool Trades for KLRS
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for KLRS, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 19:33:52 | $1.57 | 2,500 | $$4K | SELL |
| 19:25:39 | $1.60 | 2,500 | $$4K | BUY |
| 19:09:41 | $1.60 | 1,250 | $$2K | BUY |
| 16:36:59 | $1.63 | 1,450 | $$2K | SELL |
| 15:03:50 | $1.60 | 1,100 | $$2K | SELL |
5 dark pool trades shown · $$14K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Kalaris Therapeutics, Inc. (KLRS) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (3 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →KLRS — frequently asked questions
What is KLRS stock price today?
Kalaris Therapeutics, Inc. (KLRS) is at $1.57, down 5.42% (-$0.09) at the Nov 13, 2026 close.
Why is KLRS stock moving today?
Latest KLRS news — Nov 11, 2026: Citizens keeps Market Outperform on Kalaris Therapeutics, cuts target to $20 · Nov 10, 2026: Kalaris Therapeutics posts smaller quarterly loss than expected
What is the KLRS price target?
The average analyst price target for KLRS is $14.00, ranging from $14 to $17, based on 3 analysts. Latest: Wedbush initiates on May 14, 2026.
What do analysts rate KLRS?
Analyst ratings for KLRS: 0 Buy, 4 Hold, 0 Sell — consensus Hold.
Did KLRS beat earnings?
KLRS last reported on Aug 11, 2026: EPS -$0.48 vs -$0.49 expected — a beat of 3.0%.
Does KLRS pay a dividend?
KLRS does not currently pay a dividend.
What are KLRS support and resistance levels?
Resistance: $1.92, $2.16, $2.40.
What are insiders doing with KLRS?
Insider activity: NEUTRAL, 2 buys and 1 sells in the last 90 days.
What is the latest news on KLRS?
Nov 11, 2026: Citizens keeps Market Outperform on Kalaris Therapeutics, cuts target to $20 · Nov 10, 2026: Kalaris Therapeutics posts smaller quarterly loss than expected · Nov 10, 2026: Kalaris Therapeutics Posts Q3 2026 Results, Gives Business Update